Good reflections. I’ve reached pretty much the same conclusion myself. Although the silence has been a bit painful for the investor, I assume things have moved forward behind the scenes.
One would assume the announcement of the CRO appointment might be the next move, perhaps already at JPMorgan; the reasoning being, would the entire top management quartet go to Morgan just to hang out, or is it time to take the next step and move the process/strategy forward?
Someone here also hinted at the CRO; I think it was even in some of Bono’s materials that in October 2025 Bono mentioned that the CRO had already been selected.
Assuming that things are being negotiated with BP (Big Pharma), I would assume that the CRO would be in the interest of both, and perhaps BP would hint between the lines which CRO they would want. I can’t say the price of that CRO, someone guessed 10 million? I’d assume monthly pricing, in which case Faron’s cash position would, at least initially, withstand that monthly cost of just under 0.5-1 million euros. More knowledgeable people can correct me.
Then again, it could also happen that we’re disappointed again and the can is kicked down the road. There have been several of these “showcases” since last summer where we’ve been waiting for “big news.”
Everyone else, throw out your thoughts on what you expect from JPMorgan or otherwise from the company during Q1. What happens next or how will things progress?